166 related articles for article (PubMed ID: 38170220)
1. Association of physical activity with MAFLD/MASLD and LF among adults in NHANES, 2017-2020.
Li M
Wien Klin Wochenschr; 2024 May; 136(9-10):258-266. PubMed ID: 38170220
[TBL] [Abstract][Full Text] [Related]
2. Independent and joint association of physical activity and adequate weekday sleep duration with metabolic dysfunction-associated steatotic liver disease.
Li Y; Guo Y; Tan S
Clin Res Hepatol Gastroenterol; 2024 Apr; 48(4):102320. PubMed ID: 38484840
[TBL] [Abstract][Full Text] [Related]
3. MAFLD predicts cardiovascular disease risk better than MASLD.
Pan Z; Shiha G; Esmat G; Méndez-Sánchez N; Eslam M
Liver Int; 2024 Jul; 44(7):1567-1574. PubMed ID: 38641962
[TBL] [Abstract][Full Text] [Related]
4. MAFLD identifies patients with significant hepatic fibrosis better than MASLD.
Pan Z; Al-Busafi SA; Abdulla M; Fouad Y; Sebastiani G; Eslam M
Hepatol Int; 2024 Jun; 18(3):964-972. PubMed ID: 38717690
[TBL] [Abstract][Full Text] [Related]
5. Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults.
Song R; Li Z; Zhang Y; Tan J; Chen Z
Liver Int; 2024 Apr; 44(4):1051-1060. PubMed ID: 38293788
[TBL] [Abstract][Full Text] [Related]
6. Severity and Remission of Metabolic Dysfunction-Associated Fatty/Steatotic Liver Disease With Chronic Kidney Disease Occurrence.
Gao J; Li Y; Zhang Y; Zhan X; Tian X; Li J; Wang R; He Y; Wang A; Wu S
J Am Heart Assoc; 2024 Mar; 13(5):e032604. PubMed ID: 38390843
[TBL] [Abstract][Full Text] [Related]
7. Steatotic liver disease-associated all-cause/cause-specific mortality in the United States.
Kim D; Wijarnpreecha K; Cholankeril G; Ahmed A
Aliment Pharmacol Ther; 2024 Jul; 60(1):33-42. PubMed ID: 38649335
[TBL] [Abstract][Full Text] [Related]
8. Breaking new ground: MASLD vs. MAFLD-which holds the key for risk stratification?
Ramírez-Mejía MM; Jiménez-Gutiérrez C; Eslam M; George J; Méndez-Sánchez N
Hepatol Int; 2024 Feb; 18(1):168-178. PubMed ID: 38127259
[TBL] [Abstract][Full Text] [Related]
9. Association of MAFLD and MASLD with all-cause and cause-specific dementia: a prospective cohort study.
Bao X; Kang L; Yin S; Engström G; Wang L; Xu W; Xu B; Zhang X; Zhang X
Alzheimers Res Ther; 2024 Jun; 16(1):136. PubMed ID: 38926784
[TBL] [Abstract][Full Text] [Related]
10. The association of triglyceride-glucose-waist circumference with metabolic associated fatty liver disease and the severity of liver steatosis and fibrosis in American adults: a population-based study.
Wu Z; Huang K; Bao S; Zhang X; Li J; Kong W; Shi Y; Xie Y
Scand J Gastroenterol; 2024 May; 59(5):561-569. PubMed ID: 38235548
[TBL] [Abstract][Full Text] [Related]
11. Analysis of physical activity and prescription opioid use among US adults: a cross-sectional study.
Wu J; Yang P; Wu X; Yu X; Zeng F; Wang H
BMC Public Health; 2024 Mar; 24(1):698. PubMed ID: 38443876
[TBL] [Abstract][Full Text] [Related]
12. Association of different domains of physical activity with diabetic kidney disease: a population-based study.
He P; Deng Y; Dong S; Li H; Liu C; Ma Y; Tang C; Zhang M
Front Endocrinol (Lausanne); 2024; 15():1364028. PubMed ID: 38863925
[TBL] [Abstract][Full Text] [Related]
13. Diabetes Prevalence by Leisure-, Transportation-, and Occupation-Based Physical Activity Among Racially/Ethnically Diverse U.S. Adults.
Divney AA; Murillo R; Rodriguez F; Mirzayi CA; Tsui EK; Echeverria SE
Diabetes Care; 2019 Jul; 42(7):1241-1247. PubMed ID: 31221695
[TBL] [Abstract][Full Text] [Related]
14. Association between diet soft drink consumption and metabolic dysfunction-associated steatotic liver disease: findings from the NHANES.
Wu Y; Tan Z; Zhen J; Liu C; Zhang J; Liao F; Dong W
BMC Public Health; 2023 Nov; 23(1):2286. PubMed ID: 37985986
[TBL] [Abstract][Full Text] [Related]
15. The relationship between sarcopenia and metabolic dysfunction-associated fatty liver disease among the young and middle-aged populations.
Feng Z; Zhao F; Wang Z; Tang X; Xie Y; Qiu L
BMC Gastroenterol; 2024 Mar; 24(1):111. PubMed ID: 38491346
[TBL] [Abstract][Full Text] [Related]
16. Associations of occupational and leisure-time physical activity with self-rated health in Korea.
Park S; Lee JH
Prev Med; 2022 May; 158():107022. PubMed ID: 35307369
[TBL] [Abstract][Full Text] [Related]
17. MAFLD criteria are better than MASLD criteria at predicting the risk of chronic kidney disease.
Pan Z; Derbala M; AlNaamani K; Ghazinian H; Fan JG; Eslam M
Ann Hepatol; 2024 May; 29(5):101512. PubMed ID: 38710473
[TBL] [Abstract][Full Text] [Related]
18. Associations between metabolic dysfunction-associated fatty liver disease, chronic kidney disease, and abdominal obesity: a national retrospective cohort study.
Cen C; Fan Z; Ding X; Tu X; Liu Y
Sci Rep; 2024 Jun; 14(1):12645. PubMed ID: 38825630
[TBL] [Abstract][Full Text] [Related]
19. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease.
Younossi ZM; Paik JM; Stepanova M; Ong J; Alqahtani S; Henry L
J Hepatol; 2024 May; 80(5):694-701. PubMed ID: 38286339
[TBL] [Abstract][Full Text] [Related]
20. From Liver to Brain: How MAFLD/MASLD Impacts Cognitive Function.
Medina-Julio D; Ramírez-Mejía MM; Cordova-Gallardo J; Peniche-Luna E; Cantú-Brito C; Mendez-Sanchez N
Med Sci Monit; 2024 Jan; 30():e943417. PubMed ID: 38282346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
